MIRA PHARMACEUTICALS, INC.
Close on Oct 19, 2026
- Market cap
- $26.98M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Mira Pharmaceuticals has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Mira Pharmaceuticals filed with the SEC
Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Positive 7-Day Dog Study Results for SKNY-1—Obesity Treatment Designed to Preserve Lean Body Mass
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Reports Successful Formulation Results for SKNY-1, its Oral Drug Candidate for Obesity and Addiction
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55’s Differentiated Mechanism of Action and Anxiolytic Activity
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
Material agreement · New financial obligation · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals, Inc. Announces Closing of $8.9 Million Initial Public Offering
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K